Corbus Pharmaceuticals stock rises for fifth straight day

8 articles · Updated · MarketWatch · May 6

Shares climbed 2.34% to $10.92 on Wednesday as Nasdaq gained 2.02% and the Dow rose 1.24%.
Corbus outperformed Vanda Pharmaceuticals but lagged Fortress Biotech and Viking Therapeutics in a broadly positive session for biotech peers.
Trading volume reached 630,405, well above its 50-day average of 253,354, though the stock remains 46.89% below its 52-week high of $20.56.

As insiders sell shares, why do analysts predict Corbus stock could triple in value this year?

Can Corbus’s new obesity drug truly challenge market giants and the dominant GLP-1 therapies?